- Home
- KRO vs CVAC Comparison
KRO vs CVAC Comparison
Compare KRO & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRO
- CVAC
- Stock Information
- Founded
- KRO 1916
- CVAC 2000
- Country
- KRO United States
- CVAC Germany
- Employees
- KRO N/A
- CVAC N/A
- Industry
- KRO Major Chemicals
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- KRO Industrials
- CVAC Health Care
- Exchange
- KRO Nasdaq
- CVAC Nasdaq
- Market Cap
- KRO 903.0M
- CVAC 818.8M
- IPO Year
- KRO N/A
- CVAC 2020
- Fundamental
- Price
- KRO $7.43
- CVAC $2.86
- Analyst Decision
- KRO Hold
- CVAC Hold
- Analyst Count
- KRO 3
- CVAC 3
- Target Price
- KRO $12.00
- CVAC $10.00
- AVG Volume (30 Days)
- KRO 202.5K
- CVAC 635.7K
- Earning Date
- KRO 03-06-2025
- CVAC 05-22-2025
- Dividend Yield
- KRO 2.72%
- CVAC N/A
- EPS Growth
- KRO N/A
- CVAC N/A
- EPS
- KRO 0.75
- CVAC N/A
- Revenue
- KRO $1,887,100,000.00
- CVAC $70,565,734.00
- Revenue This Year
- KRO $18.33
- CVAC $752.54
- Revenue Next Year
- KRO $6.63
- CVAC N/A
- P/E Ratio
- KRO $9.81
- CVAC N/A
- Revenue Growth
- KRO 13.24
- CVAC 75.11
- 52 Week Low
- KRO $7.17
- CVAC $2.22
- 52 Week High
- KRO $14.50
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- KRO 33.96
- CVAC 43.25
- Support Level
- KRO $7.61
- CVAC $2.78
- Resistance Level
- KRO $7.94
- CVAC $3.33
- Average True Range (ATR)
- KRO 0.21
- CVAC 0.15
- MACD
- KRO 0.02
- CVAC 0.00
- Stochastic Oscillator
- KRO 21.79
- CVAC 27.69
About KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.